Travere Therapeutics (NASDAQ:TVTX) Insider Elizabeth Reed Sells 37,500 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Elizabeth Reed sold 37,500 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $2,337,750.00. Following the completion of the transaction, the insider directly owned 105,389 shares in the company, valued at $6,569,950.26. This trade represents a 26.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Performance

TVTX stock opened at $64.74 on Friday. Travere Therapeutics, Inc. has a twelve month low of $22.06 and a twelve month high of $68.73. The firm has a market cap of $6.10 billion, a price-to-earnings ratio of -140.74 and a beta of 1.05. The business’s fifty day simple moving average is $61.63 and its two-hundred day simple moving average is $48.50. The company has a quick ratio of 3.99, a current ratio of 4.05 and a debt-to-equity ratio of 24.58.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03. The firm had revenue of $169.58 million during the quarter, compared to analyst estimates of $157.27 million. Travere Therapeutics had a negative net margin of 7.35% and a negative return on equity of 55.15%. The business’s revenue was up 48.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.13 earnings per share. Analysts predict that Travere Therapeutics, Inc. will post -0.54 earnings per share for the current year.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of TVTX. Integrated Wealth Concepts LLC acquired a new position in shares of Travere Therapeutics during the second quarter worth $70,000. JW Asset Management LLC acquired a new stake in shares of Travere Therapeutics during the second quarter worth $1,704,000. Nykredit A S acquired a new stake in shares of Travere Therapeutics during the second quarter worth $237,000. Allianz Asset Management GmbH purchased a new position in shares of Travere Therapeutics during the 2nd quarter valued at about $2,441,000. Finally, Corient Private Wealth LP lifted its holdings in shares of Travere Therapeutics by 1.4% in the 2nd quarter. Corient Private Wealth LP now owns 48,125 shares of the company’s stock valued at $2,734,000 after buying an additional 648 shares during the period.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TVTX. Citigroup boosted their price target on Travere Therapeutics from $70.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings cut Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Canaccord Genuity Group raised their price target on Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. TD Cowen lifted their price objective on Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Wells Fargo & Company lifted their price target on Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a report on Friday, June 12th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $68.00.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.